After successful preclinical trials, the API enters clinical development, where it is tested in a series of progressively larger phases in human subjects. Each phase is designed to gather more data about the drug's safety and effectiveness. Depending on the results of these studies, the drug may eventually receive approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), paving the way for commercial production.
api drug substance
PQQ is a quinone compound that is gaining recognition for its role in cellular energy metabolism and neuroprotection. It possesses antioxidant properties, which help protect cells from oxidative stress, a contributing factor to many chronic diseases. PQQ is involved in the functioning of mitochondria, often referred to as the powerhouse of cells. Mitochondria convert nutrients into energy, and PQQ appears to promote mitochondrial biogenesis, enhancing energy production.
Moreover, the application of PTSA can also have a favorable environmental impact. By improving the efficiency of existing treatment processes, PTSA can help minimize the generation of waste and reduce the overall energy consumption associated with water treatment.